These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

294 related items for PubMed ID: 7682339

  • 1. A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine.
    Shima M, Scandella D, Yoshioka A, Nakai H, Tanaka I, Kamisue S, Terada S, Fukui H.
    Thromb Haemost; 1993 Mar 01; 69(3):240-6. PubMed ID: 7682339
    [Abstract] [Full Text] [Related]

  • 2. Epitope localization of monoclonal antibodies against factor VIII light chain which inhibit complex formation by factor VIII with von Willebrand factor.
    Shima M, Yoshioka A, Nakai H, Tanaka I, Sawamoto Y, Kamisue S, Terada S, Fukui H.
    Int J Hematol; 1991 Dec 01; 54(6):515-22. PubMed ID: 1724391
    [Abstract] [Full Text] [Related]

  • 3. A synthetic factor VIII peptide of eight amino acid residues (1677-1684) contains the binding region of an anti-factor VIII antibody which inhibits the binding of factor VIII to von Willebrand factor.
    Foster PA, Fulcher CA, Houghten RA, Zimmerman TS.
    Thromb Haemost; 1990 Jun 28; 63(3):403-6. PubMed ID: 2119526
    [Abstract] [Full Text] [Related]

  • 4. Different factor VIII neutralizing effects on anti-factor VIII inhibitor antibodies associated with epitope specificity and von Willebrand factor.
    Yada K, Nogami K, Shima M.
    Br J Haematol; 2013 Oct 28; 163(1):104-11. PubMed ID: 23889549
    [Abstract] [Full Text] [Related]

  • 5. Human factor VIII inhibitor alloantibodies with a C2 epitope inhibit factor Xa-catalyzed factor VIII activation: a new anti-factor VIII inhibitory mechanism.
    Nogami K, Shima M, Nishiya K, Sakurai Y, Tanaka I, Giddings JC, Saenko EL, Yoshioka A.
    Thromb Haemost; 2002 Mar 28; 87(3):459-65. PubMed ID: 11916079
    [Abstract] [Full Text] [Related]

  • 6. Factor VIII Ise (R2159C) in a patient with mild hemophilia A, an abnormal factor VIII with retention of function but modification of C2 epitopes.
    Suzuki H, Shima M, Arai M, Kagawa K, Fukutake K, Kamisue S, Nakai H, Morichika S, Tanaka I, Inoue M, Gale K, Tuddenham EG, Yoshioka A.
    Thromb Haemost; 1997 May 28; 77(5):862-7. PubMed ID: 9184393
    [Abstract] [Full Text] [Related]

  • 7. A role for the C2 domain of factor VIII in binding to von Willebrand factor.
    Saenko EL, Shima M, Rajalakshmi KJ, Scandella D.
    J Biol Chem; 1994 Apr 15; 269(15):11601-5. PubMed ID: 7512568
    [Abstract] [Full Text] [Related]

  • 8. A monoclonal antibody (NMC-VIII/10) to factor VIII light chain recognizing Glu1675-Glu1684 inhibits factor VIII binding to endogenous von Willebrand factor in human umbilical vein endothelial cells.
    Shima M, Yoshioka A, Nakajima M, Nakai H, Fukui H.
    Br J Haematol; 1992 Aug 15; 81(4):533-8. PubMed ID: 1390241
    [Abstract] [Full Text] [Related]

  • 9. Mapping and functional studies of two alloantibodies developed in patients with type 3 von Willebrand disease.
    Tout H, Obert B, Houllier A, Fressinaud E, Rothschild C, Meyer D, Girma JP.
    Thromb Haemost; 2000 Feb 15; 83(2):274-81. PubMed ID: 10739386
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Use of surface plasmon resonance for studies of protein-protein and protein-phospholipid membrane interactions. Application to the binding of factor VIII to von Willebrand factor and to phosphatidylserine-containing membranes.
    Saenko E, Sarafanov A, Greco N, Shima M, Loster K, Schwinn H, Josic D.
    J Chromatogr A; 1999 Aug 06; 852(1):59-71. PubMed ID: 10480230
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Monoclonal antibodies against the human factor VIII von Willebrand molecule: characterization and potential for screening of von Willebrand patients.
    Avner P, Arnaud D, Sultan Y, Maisonneuve P, Jeanneau C.
    Dev Biol Stand; 1984 Aug 06; 57():69-76. PubMed ID: 6084622
    [Abstract] [Full Text] [Related]

  • 18. A soluble recombinant factor VIII fragment containing the A2 domain binds to some human anti-factor VIII antibodies that are not detected by immunoblotting.
    Scandella D, Timmons L, Mattingly M, Trabold N, Hoyer LW.
    Thromb Haemost; 1992 Jun 01; 67(6):665-71. PubMed ID: 1509407
    [Abstract] [Full Text] [Related]

  • 19. The acidic region of the factor VIII light chain and the C2 domain together form the high affinity binding site for von willebrand factor.
    Saenko EL, Scandella D.
    J Biol Chem; 1997 Jul 18; 272(29):18007-14. PubMed ID: 9218428
    [Abstract] [Full Text] [Related]

  • 20. Identification of a factor VIII peptide, residues 2315-2330, which neutralizes human factor VIII C2 inhibitor alloantibodies: requirement of Cys2326 and Glu2327 for maximum effect.
    Nogami K, Shima M, Nakai H, Tanaka I, Suzuki H, Morichika S, Shibata M, Saenko EL, Scandella D, Giddings JC, Yoshioka A.
    Br J Haematol; 1999 Oct 18; 107(1):196-203. PubMed ID: 10520041
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.